Company Overview

Eiko LifeSciences Limited (CIN: L65993MH1977PLC258134) is a specialty chemicals and API manufacturing company with shares listed on BSE Limited (Scrip Code: 540204). The company has expanded into pharmaceutical formulations, logistics, and R&D solutions through subsidiaries and associates.

49th Annual General Meeting

  • Date: September 22, 2026
  • Time: 4:00 PM IST
  • Mode: Video Conferencing/Other Audio Visual Means
  • Venue: Registered Office at 604, Centrum IT Park, S G Barve Road, Near Mulund Check Naka, Wagle Estate, Thane West 400604

Business Segments

The company operates through three main business segments:

1. Specialty Chemicals & APIs

2. Logistics & Container Leasing (through subsidiary EikoVivify Logistics)

3. R&D and Scientific Solutions (through Eiko Scientific Solutions LLP)

Financial Performance FY 2025-26

Standalone Results:

  • Revenue from operations: ₹4,212.68 lakhs (29.65% growth from ₹3,249.18 lakhs in FY25)
  • Profit After Tax: ₹358.11 lakhs (105.72% growth from ₹174.08 lakhs in FY25)
  • EBITDA margin: 11.19% (improved from 7.13% in FY25)
  • Basic EPS: ₹2.60 (up from ₹1.34 in FY25)
  • Diluted EPS: ₹2.54 (up from ₹1.34 in FY25)

Consolidated Results:

  • Revenue from operations: ₹5,257.14 lakhs (39.58% growth from ₹3,766.40 lakhs in FY25)
  • Profit After Tax: ₹532.47 lakhs (129.65% growth from ₹231.86 lakhs in FY25)
  • Basic EPS: ₹3.26 (up from ₹1.62 in FY25)
  • Diluted EPS: ₹3.19 (up from ₹1.62 in FY25)

Strategic Developments

Acquisition of SSM Formulations

  • Acquired 51% stake in SSM Formulations Private Limited for ₹18.15 crore
  • SSM has WHO-GMP accredited manufacturing facility at Hinganghat, Wardha, Maharashtra
  • This marks the company's entry into pharmaceutical formulations business
  • Investment represents forward integration from specialty chemicals to finished dosage forms

Capital Raising

  • Preferential allotment of 29,50,000 warrants convertible into equity shares at ₹55 per share (including ₹45 premium)
  • Preferential allotment of 6,25,000 equity shares at ₹55 per share (including ₹45 premium)
  • Received ₹4.06 crore (25% of total amount) on allotment of warrants
  • Funds to be used for:
  • SSM Formulations acquisition (₹14.44 crore)
  • General corporate purposes (₹3.71 crore)

Share Capital Changes

  • Issued, subscribed and paid-up equity share capital increased from ₹13.72 crore to ₹14.35 crore
  • Authorized share capital increased from ₹14.00 crore to ₹20.00 crore

Subsidiaries and Associates

Wholly Owned Subsidiaries:

1. Eiko Scientific Solutions LLP (LLPIN: ACH-4311)

2. EikoVivify Logistics Private Limited (CIN: U77308MH2024PTC434438)

Associates:

1. Reflux Pharmaceuticals Private Limited (25.01% stake, investment of ₹7.01 crore)

2. SSM Formulations Private Limited (31.67% stake, investment of ₹8.09 crore)

Board and Management Changes

  • Mr. Umesh Ravindranath More resigned as Whole Time Director effective July 29, 2025
  • Mr. Sumukh Vartak appointed as Whole Time Director effective July 29, 2025
  • Ms. Hasti Doshi resigned as Independent Director effective August 24, 2026
  • Mr. Suraj Mahadev Gaikwad appointed as Additional Independent Director effective August 24, 2026

AGM Agenda Items

Ordinary Business:

1. Adoption of audited standalone and consolidated financial statements for FY 2025-26

2. Re-appointment of Mr. Bhavesh Dhirajlal Tanna as Director liable to retire by rotation

Special Business:

3. Appointment of Mr. Suraj Mahadev Gaikwad as Independent Director for 5 years

4. Approval of material related party transactions for FY 2026-27

Related Party Transactions

Approval sought for transactions with related parties including:

  • Loans to promoters up to ₹5 crore each
  • Transactions with subsidiary companies up to ₹50 crore
  • Salary payments to KMPs
  • Transactions with associate companies

Corporate Governance

  • Board met 6 times during FY 2025-26
  • All committees (Audit, Nomination & Remuneration, Stakeholders Relationship) functional
  • Company has whistleblower policy and vigil mechanism in place
  • No fraud reported during the year

Auditors and Compliance

  • Statutory Auditors: M/s P S V Jain and Associates (FRN: 131505W)
  • Secretarial Auditors: M/s Shravan A. Gupta and Associates
  • Internal Auditors: M/s NP Rajput & Co
  • All auditors confirmed no qualifications or adverse remarks in their reports

Shareholding Pattern (as on March 31, 2026)

  • Promoters: 39.91%
  • Non-Promoters: 60.09%
  • Public holding: 99.9997% in dematerialized form

Dividend

No dividend recommended for FY 2025-26

Key Financial Ratios

Standalone:

  • Current Ratio: 2.65
  • Debt-Equity Ratio: 0.02
  • Return on Equity: 6%
  • Inventory Turnover Ratio: 9.34

Consolidated:

  • Current Ratio: 3.08
  • Debt-Equity Ratio: 0.07
  • Return on Equity: 7%
  • Inventory Turnover Ratio: 8.47

Forward Outlook

The company aims to focus on execution of its expanded business portfolio including specialty chemicals, pharmaceutical formulations, and logistics services. The management remains confident about growth opportunities while being conscious of challenges in global chemical markets.